Filter By Category
Archives
Share on -
AMDIZALISIB
Generic Name: AMDIZALISIB
ABSTRACT -
Amdizalisib (HMPL-689) is an investigational, orally administered small-molecule inhibitor of phosphoinositide 3-kinase delta (PI3K-delta). It is being developed for hematologic malignancies, especially B-cell lymphoma settings in which PI3K-delta signaling contributes to malignant B-cell survival, proliferation, and microenvironment-mediated signaling. It is not a routine marketed medicine and should be considered an investigational oncology agent unless approved by a local regulator.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
Dosage should be determined only by a qualified healthcare professional.
- No globally approved routine dosing regimen is established for general clinical use.
- Clinical use should occur only under an authorized oncology clinical-trial protocol or local regulatory approval.
- Administration in studies is oral; dose, cycle schedule, dose interruption, and laboratory monitoring are protocol-specific.
SIDE EFFECTS–
Possible side effects and safety concerns include:
- Diarrhoea, nausea, abdominal discomfort, or reduced appetite
- Fatigue or weakness
- Rash, pruritus, or skin inflammation
- Raised liver enzymes
- Neutropenia, lymphopenia, anaemia, or thrombocytopenia
- Respiratory or opportunistic infections
- Class-related risks may include colitis, pneumonitis, hepatotoxicity, and serious infection.
ALLRGIC REACTIONS–
Hypersensitivity to Amdizalisib or related compounds/products may occur. Symptoms may include:
- Skin rash or urticaria
- Itching or flushing
- Swelling of the face, lips, tongue, or throat
- Wheezing or breathing difficulty
- Severe dizziness or anaphylaxis
Important: Patients who develop an allergic reaction to Amdizalisib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Amdizalisib may interact with certain medicines, vaccines, protocols, or clinical conditions. Caution is needed with:
- Strong CYP3A inhibitors or inducers may alter exposure; follow the trial protocol or local label.
- Other immunosuppressive or myelosuppressive medicines may increase infection or cytopenia risk.
- Live vaccines should generally be avoided during significant immune suppression.
- Concomitant hepatotoxic medicines may increase the need for liver-function monitoring.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Check baseline infection history, complete blood count, and liver function before treatment.
- Monitor for fever, diarrhoea, cough, dyspnoea, rash, and laboratory abnormalities during therapy.
- Use effective contraception when pregnancy risk exists because fetal risk is uncertain.
- Interrupt treatment and obtain specialist review for severe diarrhoea, pneumonitis symptoms, significant infection, or marked liver enzyme elevation.
WARNINGS –
- Investigational drug: do not use outside specialist oncology supervision.
- Serious infections, severe diarrhoea/colitis, hepatotoxicity, pneumonitis, and cytopenias are potential PI3K-inhibitor class risks.
- May cause fetal harm; avoid pregnancy during exposure unless the protocol specifically justifies the risk.
- Keep out of reach of children.
Share on -
. Developed by